Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.

Okerson T, Yan P, Stonehouse A, Brodows R

American journal of hypertension17 Dec 2009Cited by 139 (Europe PMC)

PMID20019672DOI10.1038/ajh.2009.245PepBankPUB-20019672

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced systolic blood pressure more than placebo.
In plain wordsIn patients with diabetes, exenatide reduced systolic blood pressure more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Systolic BP difference
−2.8 mm Hg
exenatide versus placebo
Source sentences
Summary
Overall, 6 months of exenatide treatment was associated with a significantly greater reduction in systolic BP (SBP) compared with placebo (least squares mean (s.e.): difference of -2.8 mm Hg (0.75); P = 0.0002) or insulin (difference of -3.7 mm Hg (0.85); P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967201
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced systolic blood pressure more than insulin.
In plain wordsIn patients with diabetes, exenatide reduced systolic blood pressure more than insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Systolic BP difference
−3.7 mm Hg
exenatide versus insulin
Source sentences
Summary
Overall, 6 months of exenatide treatment was associated with a significantly greater reduction in systolic BP (SBP) compared with placebo (least squares mean (s.e.): difference of -2.8 mm Hg (0.75); P = 0.0002) or insulin (difference of -3.7 mm Hg (0.85); P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967202
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, diastolic blood pressure did not differ significantly between exenatide and placebo.
In plain wordsIn patients with diabetes, diastolic blood pressure did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDiastolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
No significant intergroup differences in diastolic BP (DBP) were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967203
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, diastolic blood pressure did not differ significantly between exenatide and insulin.
In plain wordsIn patients with diabetes, diastolic blood pressure did not differ significantly between exenatide and insulin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDiastolic blood pressure
Study
n: not reported in source
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
No significant intergroup differences in diastolic BP (DBP) were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967204
05HumanNon-randomized trialEfficacy outcome
In diabetic patients with systolic pressure at least 130 mm Hg, exenatide reduced systolic pressure more than placebo.
In plain wordsIn diabetic patients with systolic pressure at least 130 mm Hg, exenatide reduced systolic pressure more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure with baseline SBP at least 130 mm Hg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Systolic BP difference
−3.8 mm Hg
baseline SBP at least 130 mm Hg; versus placebo
Source sentences
Summary
The majority of the intergroup difference was observed in subjects with SBP > or = 130 mm Hg (difference of -3.8 mm Hg (1.08) from placebo: P = 0.0004; difference of -4.0 mm Hg (1.01) from insulin; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967205
06HumanNon-randomized trialEfficacy outcome
In diabetic patients with systolic pressure at least 130 mm Hg, exenatide reduced systolic pressure more than insulin.
In plain wordsIn diabetic patients with systolic pressure at least 130 mm Hg, exenatide reduced systolic pressure more than insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure with baseline SBP at least 130 mm Hg
Study
n: not reported in source
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Systolic BP difference
−4 mm Hg
baseline SBP at least 130 mm Hg; versus insulin
Source sentences
Summary
The majority of the intergroup difference was observed in subjects with SBP > or = 130 mm Hg (difference of -3.8 mm Hg (1.08) from placebo: P = 0.0004; difference of -4.0 mm Hg (1.01) from insulin; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967206
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide's largest intertreatment differences occurred with baseline systolic pressure at least 150 mm Hg.
In plain wordsIn patients with diabetes, exenatide's largest differences from comparators occurred with baseline systolic pressure at least 150 mm Hg.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableIntertreatment systolic pressure difference by baseline pressure
Study
n: not reported in source
Comparator
Comparators
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The largest intertreatment differences between exenatide and comparators were observed in subjects with SBP >/=150 mm Hg.
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967207
08HumanNon-randomized trialEfficacy outcome
African-American subjects with type 2 diabetes showed similar blood pressure responses in the exenatide analysis.
In plain wordsAfrican-American patients with diabetes showed similar blood pressure responses in the exenatide analysis.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBlood pressure response in African-American subjects
Study
n: not reported in source
Comparator
Comparators
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Similar responses were observed in African-American subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
Report a problemFND-2001967208

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

09HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism
In exenatide-treated patients with type 2 diabetes, weight loss weakly correlated with systolic blood pressure reduction.
In plain wordsIn patients with diabetes taking exenatide, greater weight loss was weakly linked to greater systolic blood pressure reduction.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight loss association with systolic BP reduction
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
Correlation coefficient
0.09 r
weight loss versus SBP reduction
Source sentences
Summary
A weak correlation between the amount of weight lost and reduction in SBP was found (r = 0.09, P = 0.002) for exenatide-treated subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
This analysis explored the effects of exenatide vs. placebo or insulin on BP measurements in pooled data from six trials including 2,171 subjects studied for at least 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2001967209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02303730

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Fudan Universityn = 76Mar 2015 to Nov 2017

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Trial page ClinicalTrials.govUpdated 28 Aug 2019

CompletedPhase 3Results postedNCT01722266

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

University at Buffalon = 721 Nov 2012 to 1 Dec 2014

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 5 Jan 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.